Emma Guttman-Yassky1, Robert Bissonnette2, Benjamin Ungar3, Mayte Suárez-Fariñas4, Marius Ardeleanu5, Hitokazu Esaki6, Maria Suprun7, Yeriel Estrada8, Hui Xu8, Xiangyu Peng8, Jonathan I Silverberg9, Alan Menter10, James G Krueger11, Rick Zhang5, Usman Chaudhry5, Brian Swanson12, Neil M H Graham5, Gianluca Pirozzi12, George D Yancopoulos5, Jennifer D D Hamilton5. 1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. Electronic address: Emma.Guttman@mountsinai.org. 2. Innovaderm Research, Montreal, Quebec, Canada. 3. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. 4. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY. 5. Regeneron Pharmaceuticals, Tarrytown, NY. 6. Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 7. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY. 8. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY. 9. Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Ill. 10. Department of Dermatology, Baylor University Medical Center, Dallas, Tex. 11. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. 12. Sanofi, Bridgewater, NJ.
Abstract
BACKGROUND:Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. OBJECTIVE: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD). METHODS: Skin biopsy specimens and blood were evaluated from 54 patients randomized 1:1 to weekly subcutaneous doses of 200 mg of dupilumab or placebo for 16 weeks. RESULTS:Dupilumab (vs placebo) significantly improved clinical signs and symptoms of AD, was well tolerated, and progressively shifted the lesional transcriptome toward a nonlesional phenotype (weeks 4-16). Mean improvements in a meta-analysis-derived AD transcriptome (genes differentially expressed between lesional and nonlesional skin) were 68.8% and 110.8% with dupilumab and -10.5% and 55.0% with placebo (weeks 4 and 16, respectively; P < .001). Dupilumab significantly reduced expression of genes involved in type 2 inflammation (IL13, IL31, CCL17, CCL18, and CCL26), epidermal hyperplasia (keratin 16 [K16] and MKi67), T cells, dendritic cells (ICOS, CD11c, and CTLA4), and TH17/TH22 activity (IL17A, IL-22, and S100As) and concurrently increased expression of epidermal differentiation, barrier, and lipid metabolism genes (filaggrin [FLG], loricrin [LOR], claudins, and ELOVL3). Dupilumab reduced lesional epidermal thickness versus placebo (week 4, P = .001; week 16, P = .0002). Improvements in clinical and histologic measures correlated significantly with modulation of gene expression. Dupilumab also significantly suppressed type 2 serum biomarkers, including CCL17, CCL18, periostin, and total and allergen-specific IgEs. CONCLUSION:Dupilumab-mediated inhibition of IL-4/IL-13 signaling through IL-4 receptor α blockade significantly and progressively improved disease activity, suppressed cellular/molecular cutaneous markers of inflammation and systemic measures of type 2 inflammation, and reversed AD-associated epidermal abnormalities.
RCT Entities:
BACKGROUND:Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. OBJECTIVE: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD). METHODS: Skin biopsy specimens and blood were evaluated from 54 patients randomized 1:1 to weekly subcutaneous doses of 200 mg of dupilumab or placebo for 16 weeks. RESULTS:Dupilumab (vs placebo) significantly improved clinical signs and symptoms of AD, was well tolerated, and progressively shifted the lesional transcriptome toward a nonlesional phenotype (weeks 4-16). Mean improvements in a meta-analysis-derived AD transcriptome (genes differentially expressed between lesional and nonlesional skin) were 68.8% and 110.8% with dupilumab and -10.5% and 55.0% with placebo (weeks 4 and 16, respectively; P < .001). Dupilumab significantly reduced expression of genes involved in type 2 inflammation (IL13, IL31, CCL17, CCL18, and CCL26), epidermal hyperplasia (keratin 16 [K16] and MKi67), T cells, dendritic cells (ICOS, CD11c, and CTLA4), and TH17/TH22 activity (IL17A, IL-22, and S100As) and concurrently increased expression of epidermal differentiation, barrier, and lipid metabolism genes (filaggrin [FLG], loricrin [LOR], claudins, and ELOVL3). Dupilumab reduced lesional epidermal thickness versus placebo (week 4, P = .001; week 16, P = .0002). Improvements in clinical and histologic measures correlated significantly with modulation of gene expression. Dupilumab also significantly suppressed type 2 serum biomarkers, including CCL17, CCL18, periostin, and total and allergen-specific IgEs. CONCLUSION:Dupilumab-mediated inhibition of IL-4/IL-13 signaling through IL-4 receptor α blockade significantly and progressively improved disease activity, suppressed cellular/molecular cutaneous markers of inflammation and systemic measures of type 2 inflammation, and reversed AD-associated epidermal abnormalities.
Authors: Quinn Thibodeaux; Mary Patricia Smith; Karen Ly; Kristen Beck; Wilson Liao; Tina Bhutani Journal: Hum Vaccin Immunother Date: 2019-03-27 Impact factor: 3.452
Authors: Maria L Espinosa; Morgan T Nguyen; Amaia Saenz Aguirre; Maria Estela Martinez-Escala; Jane Kim; Christina J Walker; David S Pontes; Jonathan I Silverberg; Jaehyuk Choi; Barbara Pro; Laura B Pincus; Joan Guitart; Xiaolong A Zhou Journal: J Am Acad Dermatol Date: 2020-03-27 Impact factor: 11.527
Authors: Changxiong J Guo; Madison R Mack; Landon K Oetjen; Anna M Trier; Martha L Council; Ana B Pavel; Emma Guttman-Yassky; Brian S Kim; Qin Liu Journal: J Invest Dermatol Date: 2019-12-26 Impact factor: 8.551